Home›The Library›IGF-1 LR3
IGF-1 LR3
Real recombinant human IGF-1 is an approved drug (Increlex/mecasermin, 2005) for a narrow, severe deficiency indication. IGF-1 LR3 is a laboratory-engineered variant that was never developed as a drug at all — a 2026 peer-reviewed review found no published human clinical trials of it whatsoever.
On this page
In brief
Should you care? Yes — the parent hormone is a real approved drug for a severe deficiency; this engineered variant has literally never been tested in a human trial.The short version
- Real recombinant IGF-1 (mecasermin/Increlex) is FDA-approved, for a narrow pediatric indication.
- IGF-1 LR3 is a distinct, engineered lab-research reagent — designed to resist IGF-binding-protein clearance, not developed as a drug candidate.
- Zero published human clinical trials, per a dedicated 2026 peer-reviewed review.
What it is, and what it isn't
IGF-1 (insulin-like growth factor 1) is a real, approved hormone in its native recombinant form — mecasermin, brand name Increlex, FDA-approved 30 August 2005 for long-term treatment of growth failure in children with severe primary IGF-1 deficiency or GH-gene deletion with neutralizing antibodies to GH. IGF-1 LR3 ("Long R3 IGF-1") is a distinct, non-natural engineered analog: an Arg3 substitution plus a 13-residue N-terminal extension, designed in laboratory research to resist IGF-binding-protein sequestration and extend biological activity as a cell-culture reagent — not as a drug candidate.
The 2026 review that settles the human-evidence question
A 2026 peer-reviewed review in Frontiers in Endocrinology on performance-enhancing peptides modulating the GH-IGF1 axis (DOI 10.3389/fendo.2026.1822475), searching the literature from January 1989 to January 2026, classified IGF-1 LR3 as a compound with no peer-reviewed human studies, supported only by preclinical extrapolation and grey-literature user narratives. The existing evidence base is cell-culture proliferation assays and rodent muscle-injury/hypertrophy models — which does not establish safety or efficacy in humans.
Why it's sold anyway
IGF-1 LR3 is marketed in bodybuilding and "research chemical" circles on the strength of its relationship to a real, potent anabolic hormone and a plausible-sounding mechanism (extended IGF-1 receptor activation, resistance to binding-protein clearance). None of that substitutes for a human trial, which — as of this 2026 review — does not exist.
What buyers should know
Unlike mecasermin, which went through an approval process with defined dosing, indications and monitoring requirements, IGF-1 LR3 has no established human dosing evidence, no safety monitoring framework, and no quality-control standard governing what's actually in a vial sold online as "IGF-1 LR3."
References
- FDA approval, Increlex (mecasermin), 30 August 2005; indication for severe primary IGF-1 deficiency or GH-gene deletion with neutralizing antibodies to GH; orphan drug designation.
- Review of performance-enhancing GH-IGF1-axis peptides, Frontiers in Endocrinology 2026, DOI 10.3389/fendo.2026.1822475 (PMC13322892) — IGF-1 LR3 classified as having no peer-reviewed human studies.